GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

New genetic test can help predict how people will respond to weight-loss medications

Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Exercise found to reduce artery hardening after weight loss in adults with obesity

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity-a leading underlying cause of cardiovascular disease.

17 Sep 2025

Can changing food texture reduce how much we eat? Dutch study investigates

A new randomized controlled trial protocol from the Netherlands will test whether altering the texture, and thus the eating rate, of ultra-processed foods can reduce daily energy intake. The study will investigate how sensory properties, such as food hardness, affect metabolism, appetite, and microbiome composition.

16 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

Study challenges conventional thinking about the onset of Type 2 diabetes

A study from The University of Texas at San Antonio Health Science Center indicates that changes in the body that lead to Type 2 diabetes occur long before current diagnostic thresholds for prediabetes are met.

11 Sep 2025

Experts warn tiny plastics in arteries may raise heart attack risk

Experts caution that nanoplastics and microplastics may constitute an emerging cardiovascular risk factor, with particles identified in arterial plaques associated with a 4.5-fold increase in major adverse cardiovascular events. Experimental evidence points to inflammation, oxidative stress, and vascular injury as key mechanisms.

10 Sep 2025

Popular weight-loss medications raise pregnancy safety concerns for women

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers.

8 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Semaglutide may one day be used to treat cocaine addiction

A drug already prescribed for type 2 diabetes and obesity may one day be used to treat cocaine addiction. In animal studies, researchers at the University of Gothenburg, Sweden, found that semaglutide reduced both cocaine use and relapse.

5 Sep 2025

As insurers struggle with GLP-1 drug costs, some seek to wean patients off

After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April.

4 Sep 2025

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

New genetic test can help predict how people will respond to weight-loss medications

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

The mind-gut connection: How emotional eating affects GLP-1 drug success

Exercise found to reduce artery hardening after weight loss in adults with obesity

Can changing food texture reduce how much we eat? Dutch study investigates

Higher-dose semaglutide helps people lose nearly 19% of body weight

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Individuals taking semaglutide for weight loss experience less food noise than before

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

Are GLP-1 drugs safe for women planning pregnancy?

Scientists uncover brain circuit that turns cravings into eating behavior

Study challenges conventional thinking about the onset of Type 2 diabetes

Experts warn tiny plastics in arteries may raise heart attack risk

Popular weight-loss medications raise pregnancy safety concerns for women

WHO expands essential medicines lists with new cancer and diabetes treatments

Semaglutide may one day be used to treat cocaine addiction

As insurers struggle with GLP-1 drug costs, some seek to wean patients off

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in